Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

Université de Montréal

$17,500.00

Development of a novel ara h 2 radiotracer for studying peanut allergies

EF 2022-23

Résumé
There currently is no accurate method to assess the pharmacokinetics of food allergens after ingestion. Our goal is to develop a radiolabeled peanut protein in high purity to study the allergen's distribution using in vitro models. We plan to radiolabel ara h 2, an allergenic peanut protein 2S albumin, with the [18F] fluoronicotinic tetrafluorophenyl (TFPFN) prosthetic group via an amide bond with a lysine side-chain residues. Briefly, 18F is transferred to the cassette-based synthesis module for the automated production of [18F]TFPFN. To reduce the total amount present as an effective radiotracer, optimization experiments will be performed to find the minimal quantities of ara h 2 needed to maximize the radiochemical conversion and provide low toxicity. The final crude reaction mixture will be purified by size-exclusion (PD-10 or HiPrep 26/10 column). [18F]FN-ara h 2 will be assayed for quality control to determine identity and purity. As well, bacterial endotoxins and sterility will be conducted as per GMP guidelines. To confirm that the parent molecule ara h 2 is not altered by the radiolabel, a tracer stability test in the formulation vehicle and gastric juices will be performed and a radioreceptor assay with specific-IgE to ara h 2 will be carried out. Harvested peripheral blood mononuclear cells will be incubated with various doses of [18F]FN-ara h 2. Cell labeling efficiency and stability experiments will be done with incubation in the presence of [18F]FN-ara h 2 at 37°C for 2, 4, or 6 hours; while cell viability will be evaluated following incubation at 24 hours and 5 days with results compared with cells incubated with the nonradioactive standard. In the future, this project could potentially contribute to significant advances in the field of peanut allergies.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
487205
Name
Massey Nicole
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of a novel ara h 2 radiotracer for studying peanut allergies
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
18f-Radiolabelin; Biodistribution And Pharmacokinetics; Cell Stability And Viability; Food Allergy; In Vitro Testing; Peanut-Allergen; Pet Imaging; Prosthetic Group; Radiosynthesis Automation; Radiotracer Development
Abstract
There currently is no accurate method to assess the pharmacokinetics of food allergens after ingestion. Our goal is to develop a radiolabeled peanut protein in high purity to study the allergen's distribution using in vitro models. We plan to radiolabel ara h 2, an allergenic peanut protein 2S albumin, with the [18F] fluoronicotinic tetrafluorophenyl (TFPFN) prosthetic group via an amide bond with a lysine side-chain residues. Briefly, 18F is transferred to the cassette-based synthesis module for the automated production of [18F]TFPFN. To reduce the total amount present as an effective radiotracer, optimization experiments will be performed to find the minimal quantities of ara h 2 needed to maximize the radiochemical conversion and provide low toxicity. The final crude reaction mixture will be purified by size-exclusion (PD-10 or HiPrep 26/10 column). [18F]FN-ara h 2 will be assayed for quality control to determine identity and purity. As well, bacterial endotoxins and sterility will be conducted as per GMP guidelines. To confirm that the parent molecule ara h 2 is not altered by the radiolabel, a tracer stability test in the formulation vehicle and gastric juices will be performed and a radioreceptor assay with specific-IgE to ara h 2 will be carried out. Harvested peripheral blood mononuclear cells will be incubated with various doses of [18F]FN-ara h 2. Cell labeling efficiency and stability experiments will be done with incubation in the presence of [18F]FN-ara h 2 at 37°C for 2, 4, or 6 hours; while cell viability will be evaluated following incubation at 24 hours and 5 days with results compared with cells incubated with the nonradioactive standard. In the future, this project could potentially contribute to significant advances in the field of peanut allergies.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Massey, Nicole
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~